Prestige Consumer Healthcare Inc. $PBH Shares Bought by King Luther Capital Management Corp

Key Points

• King Luther Capital Management boosted its stake in Prestige Consumer Healthcare by 150.3% in the fourth quarter, ending with 90,968 shares valued at about $5.6 million.
• Prestige Consumer Healthcare reported mixed quarterly results, with EPS of $1.23 missing estimates and revenue of $281.6 million also coming in below expectations; revenue fell 5% year over year.
• Analysts have become more cautious on PBH, with recent rating cuts and a consensus view of Hold; the average target price currently stands at $70.75.

King Luther Capital Management Corp raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 150.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 90,968 shares of the company's stock after purchasing an additional 54,621 shares during the period. King Luther Capital Management Corp owned 0.19% of Prestige Consumer Healthcare worth $5,612,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Bayforest Capital Ltd acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at $29,000. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company's stock valued at $34,000 after purchasing an additional 283 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares during the last quarter. Torren Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $35,000. Finally, Danske Bank A S purchased a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares of the company's stock, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.40% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $48.58 on Friday. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $87.12. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54. The stock's 50 day moving average is $54.89 and its two-hundred day moving average is $60.56. The firm has a market capitalization of $2.30 billion, a PE ratio of 12.43, a P/E/G ratio of 1.55 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts' consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same period last year, the business posted $1.32 EPS. Prestige Consumer Healthcare's revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PBH shares. Weiss Ratings downgraded Prestige Consumer Healthcare from a "hold (c)" rating to a "hold (c-)" rating in a report on Thursday, May 14th. Zacks Research cut shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a report on Monday, May 18th. Canaccord Genuity Group cut their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating on the stock in a report on Friday, January 30th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.